Therapy Detail

Therapy Name LF3
Therapy Description

LF3 is a small molecule that inhibits the interaction between Beta-catenin and TCF, resulting in reduced Wnt target gene expression, decreased migration of tumor cells, and potentially resulting in decreased tumor growth (PMID: 26645562).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LF3 CTNNB1 Inhibitor 26 LF3 is a small molecule that inhibits the interaction between Beta-catenin and TCF, resulting in reduced Wnt target gene expression, decreased migration of tumor cells, and potentially resulting in decreased tumor growth (PMID: 26645562).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colon cancer not applicable LF3 Preclinical - Cell line xenograft Actionable In a preclinical study, LF3 decreased expression of Wnt target genes and reduced tumor growth in colon cancer cell line xenograft models derived from cells with high levels of Wnt signaling (PMID: 26645562). 26645562
Clinical Trial Phase Therapies Title Recruitment Status